Dermata Therapeutics — Third Quarter 2026 Earnings Summary

Dermata Therapeutics launched its first commercial product, Tome Foundational Treatment, on August 25, 2026, marking its transition to a revenue-generating skincare business. The company reported $74,000 in net sales and a $40,000 gross profit for the third quarter of 2026, with approximately 30% of orders generated through subscriptions. Clinical study results demonstrated improvements in skin appearance for over 71% of participants, supporting the product's positioning as studied skincare. Additionally, the company initiated a clinical trial for its second product, Tome Clearing Treatment, which is expected to launch in the first half of 2027.